Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Sep 12, 2023 1:35pm
220 Views
Post# 35631943

RE:RE:RE:Polish Researchers Cite Rutherrin PDT for Brain Cancer

RE:RE:RE:Polish Researchers Cite Rutherrin PDT for Brain CancerYes it does seem ludicrous. Having an sp of 23 cents CAN at this stage of the game also seems ludicrous. Could big pharma.anti-PDT prejudice really be that strong? At some point some corporate  sharpie is going to realize that a lot of money.could be made here. Or maybe they already realize it? If so, why are they risking a rival getting in first?

StevenBirch wrote: As I have said it's my opinion that it would be a waste of time raising $462K unless it was only to get them through this next quarter with the expectation that they will be able raise money for GBM or NSCLC from a much more favorable position. If the time frame were longer they would be forced to do a deal with the devil but we know from this last update that they are close to getting BTD. The idea that they were begging for money and all they could get was $462K seems ludicrous to me given what they have achieved in this trial and what they have on the go.


Oilminerdeluxe wrote: Now that is a study I want to see start asap. That little thing called money though. Hopefully soon solved.




<< Previous
Bullboard Posts
Next >>